SAN DIEGO--(BUSINESS WIRE)--Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Harlan Waksal, M.D. has resigned as Chairman of the Board of Directors of Sevion effective March 4, 2016, due to the increased responsibilities and workload that comes with Dr. Waksal’s role as President and Chief Executive Officer at Kadmon Corporation, LLC. “We greatly appreciate Dr. Waksal’s presence and strong leadership during his tenure on the board and we wish him well in his business pursuits,” noted Chief Executive Officer David Rector.
